Spine BioPharma, Inc., a development stage company committed to non-opiate, non-surgical therapies for Degenerative Disc ...
Canaccord analyst Kingsley Crane raised the firm’s price target on CrowdStrike (CRWD) to $420 from $370 and keeps a Buy rating on the shares.
Canaccord raised the firm’s price target on Okta (OKTA) to $100 from $94 and keeps a Hold rating on the shares. The firm said they reported ...
Find insight on lithium, lumber, the impact of tariffs and more in the latest Market Talks covering Basic Materials.
The looming end to Australia’s $40bn hybrid securities market represents a big opportunity for stockbroking veteran Geoff ...
Morgan Stanley reaffirmed Tesla as its top pick, maintaining a $430 price target despite mixed analyst ratings. Some firms, ...
TTEC (NASDAQ:TTEC – Free Report) had its target price reduced by Canaccord Genuity Group from $4.50 to $3.50 in a research ...
CrowdStrike (NASDAQ:CRWD – Free Report) had its price target boosted by Canaccord Genuity Group from $370.00 to $420.00 in a ...
Not for distribution to United States newswire services or for dissemination in the United States. TORONTO, March 03, 2025 (GLOBE NEWSWIRE) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback